Author Archive

Special offer of the mAb IST-9 specific for ED-A of fibronectin

By : June 1, 2011

 1 milligram for 550 EURO !! IST-9 mAb reacts both with sections from  frozen and paraformaldehyde fixed tissues. IST-9 reacts with the C’-C’ loop of  ED-A preventing ED-A binding with integrins alpha5-beta1, alpha4-beta1 and alpha9-beta1. IST-9 inhibits fibroblasts differentiation into myo-fibroblasts and TGF-beta activation, thus inhibiting fibrosis (see under the Antibodies section). More recently it has […]


By : April 12, 2010

Sirius-biotech has acquired from the National Cancer Institute of  Genoa the patent for the mAb C6. The mAb C6 recognizes a novel fibronectin epitope unmasked by the insertion of the extra-domain B. This antibody, specifically reacting with neoforming blood vessels, represents a new tool for the targeting of tissues undergoing neoangiogenesis and for the study of novel fibronectin […]

Discovered and localized a novel fibronectin tumor associated epitope

By : February 25, 2010

This epitope is recognized by the mAb C6 that, in addition to providing a new reagent for angiogenesis targeting, represents a new tool for the study of the potential biological functions of fibronectin.

Sirius-biotech to offer mAb BC-1 specific for the angiogenesis

By : December 14, 2009

Sirius-biotech to offer the mAb BC-1 specific for the angiogenesis, associated B-FN as well as a large panel of antibodies for different epitopes of human fibronectin

IST antibodies acquired

By : November 11, 2009

SIRIUS-biotech defined a contract with the National Institute for Cancer Research (IST), located in Genoa, for the commercialization of a large panel of murine monoclonal antibodies to human tenascin and fibronectin.

Uteroglobin procedure published

By : September 20, 2009

SIRIUS-biotech personnel collaborated in the publication of the uteroglobin procedure for the generation of polyvalent polyspecific fusion proteins (patent pending). For further references, please consult: Ref. Ventura E. et al. “Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins”, 2009, J Biol Chem, 284:26646-26654.

Company launched

By : September 1, 2009

Cell biology scientist with a 20 years expertise, Luciano Zardi and Rodolfo Quarto, internationally recognized expert in stem cells, tissue engineering and extracellular matrix of normal and neoplastic tissues, decided to start-up Sirius-biotech, a new biotechnology company bringing professional skills to private and public bodies. The founders launched the business in August, 2009.